SCHEMBL1312966

SCHEMBL1312966

Cc1cccc(-c2ccc(C=O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.52
DRD1 P21728 1/20 0.51
TRIM24 O15164 1/20 0.47
TRIM33 Q9UPN9 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
PGR P06401 1/20 0.45
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
ENPP3 O14638 1/20 0.45
KIF11 P52732 1/20 0.43
FYN P06241 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
ACHE P22303 1/20 0.42
ELANE P08246 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3824008 0.86 TRIM24 (0.53) CYP2A6TRIM24TRIM33CA12CA1
SCHEMBL1669178 0.85 DRD1 (0.59) CYP2A6DRD1TRIM24TRIM33CA12
SCHEMBL6561397 0.82 ACHE (0.61) PGRHSD17B1HSD17B2ENPP3FYN
SCHEMBL5711166 0.82 CYP2A6 (0.55) CYP2A6DRD1TRIM24TRIM33CA12
SCHEMBL29700451 0.81 TRIM24 (0.67) CYP2A6DRD1TRIM24TRIM33CA12
SCHEMBL29936396 0.81 ALDH1A1 (0.56) CYP2A6DRD1TRIM24TRIM33CA12
SCHEMBL29936157 0.81 ALDH1A1 (0.56) CYP2A6DRD1TRIM24TRIM33CA12
SCHEMBL3975070 0.81 CYP2A6 (0.58) CYP2A6DRD1KIF11MAPTPOLB
SCHEMBL5916092 0.81 TRIM24 (0.67) CYP2A6DRD1TRIM24TRIM33CA12
SCHEMBL13617691 0.81 ALDH1A1 (0.56) CYP2A6DRD1TRIM24TRIM33CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287230-B2 Selective aerobic oxidation of dimethylbiphenyls EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2019-05-14 US disclosed
US-20180179141-A1 SELECTIVE AEROBIC OXIDATION OF DIMETHYLBIPHENYLS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2018-06-28 US disclosed
WO-2017099693-A1 SYNTHESES OF METAL HETEROCYCLIC CARBENE ENOLATES AS COUPLING REACTIONS CATALYSTS COSKUN NEJDET (TR) 2017-06-15 WO disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-20120309701-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS THE WASHINGTON UNIVERSITY (US) 2012-12-06 US disclosed
US-20120295915-A1 AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2012-11-22 US disclosed
EP-2503890-A1 AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline LLC (US) 2012-10-03 EP disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed
EP-2375899-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF Array Biopharma, Inc. (US) 2011-10-19 EP disclosed
WO-2011066211-A1 AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-06-03 WO disclosed
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. 2005-09-22 US disclosed
WO-2005064008-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-07-14 WO disclosed
EP-1509537-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2005-03-02 EP disclosed
US-6743807-B2 TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-06-01 US disclosed
WO-2003090690-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed
EP-1335899-A2 SUBSTITUTED ALKYLDIAMINES AS INHIBITORS OF PLASMEPSIN OR RELATED PROTEASES Actelion Pharmaceuticals Ltd. (CH) 2003-08-20 EP disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed
EP-1322612-A1 SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA Actelion Pharmaceuticals Ltd. (CH) 2003-07-02 EP disclosed
WO-2002038534-A2 SUBSTITUTED ALKYLDIAMINES AS INHIBITORS OF PLASMEPSIN OR RELATED PROTEASES ACTELION PHARMACEUTICALS LTD (CH) 2002-05-16 WO disclosed
WO-2002024649-A1 SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA ACTELION PHARMACEUTICALS LTD (CH) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295915-A1 AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, COASY CYP2A6 456/4885DRD1 2719/4885TRIM24 2472/4885
US-20180179141-A1 SELECTIVE AEROBIC OXIDATION OF DIMETHYLBIPHENYLS CYP1B1, MSMO1, CYP1A1 CYP2A6 168/4885DRD1 696/4885TRIM24 951/4885
US-20120309701-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS MMP8, ELANE, GUSB CYP2A6 2361/4885DRD1 4066/4885TRIM24 4195/4885
US-10287230-B2 Selective aerobic oxidation of dimethylbiphenyls CYP1B1, MSMO1, CYP1A1 CYP2A6 168/4885DRD1 696/4885TRIM24 951/4885
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds PPA1, PPME1, PNP CYP2A6 3590/4885DRD1 4672/4885TRIM24 1933/4885
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF NOS1, NOS2, ASS1 CYP2A6 1411/4885DRD1 331/4885TRIM24 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.